{
  "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
  "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 39,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide outlines the key therapeutic advantages of the drug candidate NVL-330.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/33",
  "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
  "deckJsonHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json",
  "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.41,
        "w": 0.058,
        "x": 0.512,
        "y": 0.335
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11b7514f-9406-4935-a23a-5196487122aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.586,
        "y": 0.495
      },
      "kind": "list",
      "text": "EGFR sparing. Related adverse events include skin rash and diarrhea",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0ad76c8-46af-48c8-81dc-4377d6be7900",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.25,
        "x": 0.586,
        "y": 0.362
      },
      "kind": "list",
      "text": "Active against HER2 and HER2ex20",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8ec2f36-1ec6-422b-ae55-3a4ec80abca9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.586,
        "y": 0.682
      },
      "kind": "list",
      "text": "Brain penetrant. ~20% of patients with HER2-positive NSCLC present with brain metastases",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef1d6a6e-53a6-4c5c-96a3-f66a12c3e61d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.25,
        "x": 0.512,
        "y": 0.233
      },
      "kind": "title",
      "text": "TARGET PRODUCT PROFILE:",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fb9b094-b14a-4528-a647-6992931f6c1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.35,
        "x": 0.106,
        "y": 0.358
      },
      "kind": "title",
      "text": "NVL-330 for Malignancies Driven by HER2 Exon 20 Insertion Mutations (HER2ex20)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68e96bac-df96-4bf4-959d-32f58cea4816",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "afa0a69f-5771-4550-9bfc-20d26e12455a",
      "evidence": "list/bullet: Brain penetrant. ~20% of patients with HER2-positive NSCLC present with brain metastases",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}